Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.
Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ. · 2016
Read Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. by Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4986340.txt.
Description
Lucie Heinzerling and nine co-authors report heart damage linked to immune checkpoint cancer drugs. Their case series appeared in the Journal for ImmunoTherapy of Cancer in 2016. Drugs blocking CTLA4 or PD1 free the immune system against melanoma, lung cancer, and kidney cancer, with clear survival gains. Immune side effects are common, but heart events had appeared only as single cases. Six experienced cancer centers pooled their records to find the pattern.
Eight cases of immune related cardiotoxicity followed ipilimumab or the PD1 drugs nivolumab and pembrolizumab. Presentations varied widely: heart failure, cardiomyopathy, heart block, myocardial fibrosis, and myocarditis. The authors call this the largest series to date. They urge awareness and heart monitoring during treatment, since an immune attack on the heart can be fatal yet may be missed among better known side effects.
Catalog record
| CREATOR | Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |